Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more
Market Cap & Net Worth: Champions Oncology Inc (CSBR)
Champions Oncology Inc (NASDAQ:CSBR) has a market capitalization of $86.10 Million ($86.10 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23299 globally and #8162 in its home market, demonstrating a 3.85% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Champions Oncology Inc's stock price $6.20 by its total outstanding shares 13886326 (13.89 Million).
Champions Oncology Inc Market Cap History: 2015 to 2026
Champions Oncology Inc's market capitalization history from 2015 to 2026. Data shows growth from $49.57 Million to $86.10 Million (1.23% CAGR).
Index Memberships
Champions Oncology Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #624 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #2053 of 3165 |
Weight: Champions Oncology Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Champions Oncology Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Champions Oncology Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.69x
Champions Oncology Inc's market cap is 1.69 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
20.41x
Champions Oncology Inc's market cap is 20.41 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $35.13 Million | $11.18 Million | -$10.45 Million | 3.14x | N/A |
| 2017 | $53.88 Million | $15.41 Million | -$6.88 Million | 3.50x | N/A |
| 2018 | $108.45 Million | $20.24 Million | -$1.48 Million | 5.36x | N/A |
| 2019 | $115.67 Million | $27.07 Million | $128.00K | 4.27x | 903.70x |
| 2020 | $149.83 Million | $32.12 Million | -$2.09 Million | 4.66x | N/A |
| 2021 | $116.09 Million | $41.04 Million | $362.00K | 2.83x | 320.69x |
| 2022 | $62.63 Million | $49.11 Million | $548.00K | 1.28x | 114.28x |
| 2023 | $78.04 Million | $53.87 Million | -$5.33 Million | 1.45x | N/A |
| 2024 | $119.01 Million | $50.16 Million | -$7.28 Million | 2.37x | N/A |
| 2025 | $95.95 Million | $56.94 Million | $4.70 Million | 1.69x | 20.41x |
Competitor Companies of CSBR by Market Capitalization
Companies near Champions Oncology Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Champions Oncology Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Champions Oncology Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Champions Oncology Inc's market cap moved from $49.57 Million to $ 86.10 Million, with a yearly change of 1.23%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $86.10 Million | -10.27% |
| 2025 | $95.95 Million | -19.37% |
| 2024 | $119.01 Million | +52.49% |
| 2023 | $78.04 Million | +24.61% |
| 2022 | $62.63 Million | -46.05% |
| 2021 | $116.09 Million | -22.52% |
| 2020 | $149.83 Million | +29.53% |
| 2019 | $115.67 Million | +6.66% |
| 2018 | $108.45 Million | +101.29% |
| 2017 | $53.88 Million | +53.36% |
| 2016 | $35.13 Million | -29.13% |
| 2015 | $49.57 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Champions Oncology Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $86.10 Million USD |
| MoneyControl | $86.10 Million USD |
| MarketWatch | $86.10 Million USD |
| marketcap.company | $86.10 Million USD |
| Reuters | $86.10 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.